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Background: Cytomegalovirus (CMV) is a major cause of infection in the early period after
heart transplantation (HTx). There are limited data comparing universal prophylaxis with
preemptive treatment of CMV infection in HTx recipients. Therefore, the goal of this study
was to evaluate efficacy and safety of both strategies.
Methods: A total of 17 HTx recipients were prospectively enrolled in the universal
prophylaxis group. This study cohort was matched with 18 HTx recipients who had the
same immunosuppressive regimen and received preemptive therapy for CMV infection. All
patients were CMV-seropositive. The study group received oral valganciclovir in a dose of
900 mg daily for 100 days. The second group was treated in case of CMV viraemia higher
than 500 copies/ml. The incidence of CMV infection, other opportunistic infections and
acute graft rejection and adverse events were evaluated at 3th, 6th and 12th months post-
transplant.
Results: Universal prophylaxis was tolerated in 87.5% of the patients for a period of 100
days. Leukopenia was the most frequent side-effect that appeared in 25% of this group.
This strategy decreased the rate of asymptomatic CMV infection during the first 3 months
after HTx (11.7% vs. 55.6%, p ¼ 0.006) compared with preemptive therapy. This positive
effect was associated with lower incidence of acute graft rejection at 12 months of follow
up (6.3% vs. 41.2%, p ¼ 0.015).
Conclusion: Universal prophylaxis, with valganciclovir in CMV-seropositive HTx recipients,
was acceptably safe and compared with preemptive therapy of CMV infection reduced the
incidence of asymptomatic CMV infection and of acute graft rejection.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z.o.o. All
rights reserved.1. Introduction
Cytomegalovirus (CMV) is a major cause of infection in the
first months after heart transplantation (HTx). The reported
incidence of CMV disease ranges between 10% and 60%
depending on donor–recipient mismatch in CMV serology and
on intensity of immunosupression [1–3]. Besides to directch Society of Cardiology.
5; fax: þ420261362989.
vym@gmail.com (J. Vymesequalae of infection, CMV viral load has been associated
with indirect effects like an increased risk of opportunistic
infections [1–3], high incidence of acute graft rejection and/or
cardiac allograft vasculopathy [4–6]. Intravenous ganciclovir
has been shown to prevent CMV disease both in CMV-
seronegative [7] and CMV-seropositive [8] HTx recipients.
The invention of valganciclovir a valine ester prodrug ofPublished by Elsevier Urban & Partner Sp.z.o.o. All rights reserved.
talova).
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easier and more widespread use of CMV prophylaxis in these
patients. As a universal prophylaxis in CMV-seronegative
recipients of organs from seropositive donors, valganciclovir
at dosage of 900 mg daily is equivalent to oral ganciclovir
administered at a dose of 1000 mg three times daily [9].
Valganciclovir has also been studied in the setting of
preemptive therapy in HTx recipients [10]. In such case the
HTx recipients are monitored for early evidence of CMV
replication and treated with antiviral therapy in case of
documented viraemia.
Universal prophylaxis might be more effective way pre-
venting both direct and indirect effects of CMV infection than
preemptive therapy. On the other hand, preemptive therapy
could reduce drug costs and toxicity. However, there are
limited data about efficacy of universal prophylaxis with
valgancilovir in CMV-seropositive HTx recipients. Similarly,
direct comparison of universal prophylaxis and preemptive
therapy is not available in this population. Therefore, we
conducted a prospective cohort study comparing the efficacy
and safety of the universal CMV prophylaxis with the
preemptive treatment in HTx recipients at risk of CMV
infection.2. Methods and materials
2.1. Study protocol
This was a prospective single-center, case–control study. The
inclusion criteria were as follows: de novo HTx, age of
recipient above 18 years and an increased risk of CMV
infection. The following combinations of CMV serology in a
donor (D) and a recipient (R) were included: Rþ/D, Rþ/Dþ
and R/Dþ. We excluded individuals who deceased before the
10th postoperative day. The other exclusion criteria com-
prised acute renal or liver failure, severe leukopenia or
trombocytopenia and known hypersensitivity to ganciclovir
or valganciclovir.
2.2. Study groups
In total, 44 individuals who underwent de novo HTx between
November 2007 and December 2008 were screened. Out of this
cohort, 41 patients were at risk of CMV infection (85%). Three
individuals died early after HTx and another three refused to
participate in the study. A total of 35 patients participated in
the study. Seventeen HTx recipients at risk of CMV infection
were prospectively enrolled in the universal prophylaxis
group. The remaining 18 individuals received preemptive
treatment of CMV infection. The whole study group had the
same induction therapy with polyclonal anti-human thymo-
cyte immunoglobulin (Thymoglobuline, Genzyme Polyclonals
S.A.S, Marcy L’ Etoile, France) 1.25 mg/kg day administered at
the time of surgery and in the following 3–7 days until target
through levels of tacrolimus were reached. Standard immu-
nosupressive regimen consisted of tacrolimus with a target
through level of 10–15 ng/ml, mycophenolate mophetil
2000 mg daily, and prednisone at an initial dose of 1 mg/
kg day with subsequent tapering to less than 0.3 mg/kg dayat 1 month and 0.1 mg/kg day at 12 months after HTx. Both
groups were followed using the same schedule of clinical and
laboratory controls, as well as the institutional protocol of
endomyocardial biopsy (EMB). Acute allograft rejection epi-
sodesZgrade Banff 3Awere treated with intravenous methyl-
prednisolone 1000 mg for 3 consecutive days.2.3. Study treatment
The universal prophylaxis group was treated with 900 mg of
oral valganciclovir once daily for 100 days starting within the
first 10 days after HTx. The group of preemptive therapy was
closely monitored to detect CMV viraemia and received
valganciclovir only in case of CMV viraemia higher than
500 copies/ml. The terapeutic dosage of valganciclovir was
900 mg twice daily for 2–3 weeks until clearance of CMV
viraemia followed by a prophylactic dose for next 3 months.
Individuals with tissue invasive CMV disease were treated
with intravenous ganciclovir 5 mg/kg twice daily for 3 weeks
followed by a prophylactic dose of valganciclovir for next
3 months. In cases of impaired renal function, dosages of
valganciclovir and ganciclovir were adjusted appropriately.2.4. Follow-up
Presence of CMV disease, CMV viraemia, other infections and
acute graft rejection, as well as adverse effects were analyzed
at 3th, 6th and 12th months post-transplant.
EMB were planned and performed according to the institu-
tional protocol. In brief, patients underwent EMB every week
until 30 days post-transplant, every 2 weeks until 3 months,
every 1 month until 6 months, followed by EMB at 9th and
12th months after HTx. Biopsies were graded according to
1990 ISHLT classification (Banff classification) using the
following scale: 0, 1A, 1B, 2, 3A, 3B, 4 [11]. Each EMB was
accompanied with a clinical and laboratory control. Labora-
tory analysis included measurements of CMV-viraemia, blood
count, serum creatinine and liver function tests (aspartate
amino-transferase, alanine amino-transferase, g-glutamyl-
transferase and alkaline phosphatase).
The pre-transplant CMV serology status of recipients and
donors was assessed using a commercial enzyme-linked
immunoassay detecting specific IgG and IgM antibodies.
CMV viraemia was measured in peripheral venous blood
samples obtained into tubes containing ethylenediaminete-
traacetic acid. The measurement of CMV DNA concentration
was performed using a commercially available real-time
polymerase chain reaction (ArtusTM CMV RG PCR kit, Qiagen,
Hilden, Germany).2.5. Definitions
CMV infection was defined as presence of CMV viraemia
4500 copies/ml regardless of symptoms. For the purpose of
statistical analysis, we divided CMV infection into asympto-
matic CMV viraemia (a positive CMV PCR without signs or
symptoms) and CMV disease (detectable CMV PCR with
attributable symptoms). Leukopenia referred to white blood
C O R E T VA S A 54 ( 2012 ) e16 –e21e18cell count of less than 4.0109 l–1 and trombocytopenia to
platelet count of less than 150109 l–1.
2.6. Statistical methods
Categorical data were expressed as percentages and com-
pared using w2 analysis. Continuous variables were expressed
as a mean and standard deviation. They were compared using
the Student t-test for paired and unpaired data or by the non-
parametric Mann–Whitney test when appropriate. A p value
o0.05 was considered statistically significant. Analysis was
performed using the statistical software SPSS (Chicago,
Illinois, USA) for Windows, version 17.0.
2.7. Ethics
The investigation conformed to the principles outlined in the
Declaration of Helsinky. It was approved by the local human
ethics committee. All subjects gave their written informed
consent prior to the participation in the study.3. Results
Table 1 shows the study population characteristics. The
universal prophylaxis group and the preemptive therapy
group were well matched. All recipients were CMV-seroposi-
tive. There was no case of Dþ/R-CMV mismatch, which
indicated an intermediate risk of post-transplant CMV infec-
tion in our study group. Two patients died during follow-up.
In the universal prophylaxis group, one patient died ofTable 1 – The study group characteristics.
Universal
prophylaxis,
n ¼ 17 pts
Preemptive therapy,
n ¼ 18 pts
p-value
Age (years)
49.5712.8 50.4710.5 NS
Gender
12 males (74%) 14 males (77.8%) NS
5 females (26%) 4 females (32.2%)
Aethiology of heart failure
CAD 4 pts (23%) CAD 9 pts (50%) NS
DCM 7 pts (42%) DCM 5 pts (28%)
Other 6 pts (35%) Other 4 pts (22%)
Immunosupression
Tacrolimus 17 pts (100%) Tacrolimus 18 (100%) NS
MMF 17 pts (100%) MMF 18 (100%)
Prednisone 17 pts (100%) Prednisone 18 (100%)
CMV serology
Dþ/R–0 Dþ/R–0 NS
D/Rþ–5 pts (29%) D/Rþ–2 pts (17%)
Dþ/Rþ–12 pts (71%) Dþ/Rþ–15 pts (83%)
Abbreviations: CAD, coronary artery disease; CMV, cytomegalovirus;
DCM, dilated cardiomyopathy; D, donor; R, recipient; MMF,
mycophenolate mophetil; NS, not significant; pts, patients.intracerebral hemorrhage on the 16th postoperative day
which was not related to treatment with valganciclovir. In
the preemptive therapy group, one patient died of sepsis of
unknown origin in the 6th postoperative week. The remaining
33 patients completed 12 months of follow-up.4. Efficacy of treatment
Compared with the preemptive therapy, universal prophy-
laxis with valganciclovir resulted in significant reduction of
asymptomatic CMV viraemia during the first 3 months of
follow-up: 2 pts (11.7%) vs. 10 pts (55.6%), p ¼ 0.006 (Table 2).
The relative risk reduction reached 80%. In addition, four
individuals (22%) from the preemptive therapy group experi-
enced a tissue invasive form of CMV disease, which was not
observed in the universal prophylaxis group. These four cases
included histologically proven CMV gastritis and CMV myo-
carditis (0–3 months of follow-up) and histologically proven
CMV colitis and interstitial pneumonia with detection of CMV
and pneumocystis jiroveci in bronchoalveolar lavage speci-
mens (4–6 months of follow-up). Importantly, there was no
increase in late-onset CMV infection after completion of
valganciclovir prophylaxis. Three months after HTx, asymp-
tomatic CMV infection affected about 12% of patients in both
groups in each time period (Table 2).
During the follow up period, four cases of opportunistic
infection were observed. Two of them occurred in the
universal prophylaxis group. The first case was pneumocystis
jiroveci pneumonia diagnosed at 7 weeks after HTx that
resolved after cotrimoxazol treatment. The second case was
pneumocystis jiroveci pneumonia complicated by invasive
pulmonary aspergilosis at 8 weeks after HTx. It was success-
fully treated with cotrimoxazol and voriconazol. The remain-
ing two cases of opportunistic infection appeared in the
preemptive therapy group. One case comprised mixed CMV
and pneumocystis jiroveci interstitial pneumonia at 4 months
of follow-up, treated again with a combination of cotrimox-
azol and voriconazol. The second case was invasive pulmon-
ary aspergilosis diagnosed at 4 months of follow-up,
successfully treated with itraconazol.
Interestingly, during the first 3 months of follow up, the
universal prophylaxis group presented with lower incidence
of acute cellular rejection grade Banff 2 compared with the
preemptive therapy group [0 pts vs. 5 pts (27.8%), p ¼ 0.019].
Within 12 months of follow-up, only one patient (6.3%) from
the universal prophylaxis group experienced one episode of
acute cellular rejection, grade Banff 2. On the contrary, 7 pts
(41.2%) from the preemptive therapy group had within the
same time period a total of 10 episodes of acute cellular
rejection grade Banff 2 (p ¼ 0.015).5. Safety
Universal prophylaxis with valganciclovir was well tolerated
by 14 individuals (87.5%) for the entire treatment period of 100
days. Valganciclovir had to be discontinued in 2 pts (12.5%)
due to significant leukopenia and neutropenia on the 57th
and 85th day of prophylaxis. In these two patients, the count
Table 2 – Efficacy of the universal prophylaxis with valganciclovir compared with preemptive therapy. Table shows
number of patients who experienced CMV infection, other opportunistic infections and acute graft rejection.
Time
period
Study
group
CMV
viraemia
CMV
disease
Other opportunistic
infections
Acute rejection
Banff 2
Acute
rejection
Banff 3A–3B
0–3
months
UP 2 0 2 0 1
n ¼ 17 (11.7%) (11.7%) (5.9%)
PT 10 2 0 5 1
n ¼ 18 (55.6%)nn (11.1%) (27.8%)n (5.6%)
4–6
months
UP 2 0 0 1 0
n ¼ 16 (12.5%) (6.3%)
PT 2 2 2 (11.7%) 1 0
n ¼ 17 (11.7%) (11.7%) (5.9%)
7–12
months
UP 2 0 0 0 0
n ¼ 16 (12.5%)
PT 2 0 0 1 0
n ¼ 17 (11.7%) (5.9%)
Abbreviations: PT, preemptive treatment; UP, universal prophylaxis.P-value for comparison between the universal prophylaxis group and the
preemptive therapy group during each period of follow-up was coded: po0.05n, po0.01nn.
CO R E T VA S A 54 ( 2012 ) e16 –e21 e19of leukocytes and neutrophils reached 2.2109 l–1 and
3.3109 l–1, and 1.52109 l–1 and 1.83109 l–1, respectively.
Another two individuals experienced leukopenia that re-
solved after dose reduction of valganciclovir to 450 mg daily
(Table 3). The first case appeared on the 79th day (leukocytes
3.5109 l–1, neutrophiles 2.13109 l–1), while the second case
was diagnosed on the 83rd day (leukocytes 3.9109 l–1,
neutrophiles 2.11109 l–1). In the first 3 months, the pre-
valence of leukopenia in the universal prophylaxis group was
higher (25%) than in the preemptive therapy group (0%).
However, this difference did not reach statistical significance
(p ¼ 0.089).
Table 3 shows the other parameters of safety. We observed
a mild elevation of aspartate amino-transferase in the
universal prophylaxis group at 3 months. However, this
elevation was only mild and did not exceed the upper limit
of normal values in any patient. No other drug-related side-
effects were observed.6. Discussion
Themain findings of our study can be summarized as follows.
First, universal prophylaxis was significantly more effective
than preemptive treatment in reduction of subclinical CMV
infection. Second, universal prophylaxis with valganciclovir
was safe and tolerated by 83% of the study group for the
entire treatment period of 100 days. Third, universal prophy-
laxis reduced incidence of acute graft rejection Banff 2 during
the first 3 months post-transplant.7. Comparison with previous studies
The first experience with preemptive treatment of CMV
infection with valganciclovir was reported by Devyatko et al.
[10]. Subsequently, Potena el al. [12] demonstrated in a cohortstudy that universal prophylaxis with valganciclovir com-
pared with preemptive intravenous ganciclovir reduces CMV
viral burden and prevents progression of cardiac allograft
vasculopathy. In another study by the same author, an
aggressive CMV prophylaxis in CMV R–/DþHTx patients
decreased risk of CMV infection, acute graft rejection and
progression of cardiac allograft vasculopathy below levels
seen in CMV-seropositive HTx patients receiving standard
prophylaxis [13]. The aggressive prophylaxis protocol con-
sisted of CMV hyperimmune immunoglobulin plus 4 weeks of
treatment with intravenous ganciclovir followed by 2 months
of valganciclovir. Standard prophylaxis consisted of intrave-
nous ganciclovir administered for 4 weeks. A direct compar-
ison of universal prophylaxis and preemptive therapy with
valganciclovir was performed by Khoury et al. [14] in a
randomized study in renal transplant recipients. The study
demonstrated greater efficacy of prophylactic valganciclovir
given for 100 days to suppress subclinical CMV infection for
12 months than preemptive therapy. However, 22% of patients
in the universal prophylaxis group experienced late-onset
CMV viraemia. This occurred more frequently in individuals
with pre-transplant serology CMV Dþ/R (in 38%). A rando-
mized trial in 364 CMV Dþ/R solid organ transplant
recipients compared valganciclovir 900 mg once daily with
oral ganciclovir 1000 mg three times a day for 100 days [9].
Valganciclovir provided greater reduction of CMV viraemia
associated with reduced occurrence of acute graft rejection.
Nevertheless, this study demonstrated high incidence of late-
onset CMV infection, which appeared approximately in 50%
of these high risk patients after completion of prophylaxis.
Our study extends the available evidence by direct compar-
ison of universal prophylaxis and preemptive therapy with
valganciclovir in CMV-seropositive HTx recipients. It confirms
results of previous studies in terms of reduced incidence of
CMV infection and acute allograft rejection achieved through
universal prophylaxis. However, its results may not be
applicable to individuals with pre-transplant CMV serology
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C O R E T VA S A 54 ( 2012 ) e16 –e21e20Dþ/R. These recipients have a high risk of CMV infection
and may need a combination of prophylactic approaches or
prolonged prophylaxis with valganciclovir. Further studies are
needed to elucidate the best management in these indivi-
duals. Moreover, prognostic impact of universal CMV prophy-
laxis can only be assessed in large randomized trials.8. CMV infection as a trigger of acute graft
rejection and cardiac allograft vasculopathy
There is a growing evidence supporting association between
CMV infection, acute graft rejection and cardiac allograft
vasculopathy. These complications are called indirect effects
and belong to the main causes of death and retransplantation
in HTx patients.
CMV infection is known to increase the risk of acute cellular
rejection. Several mechanisms have been implicated in the
inflammatory response to allograft triggered by CMV. They
include altered expression of growth factors and cytokines,
up-regulation of proinflammatory adhesion molecules and/or
modulation of the nitric oxide synthase pathway [3,15–19]. Even
latent CMV infection has been shown in a murine model to be
associated with disruption of allograft tolerance and increased
intramyocardial expression of proinflammatory genes in allo-
grafts but not in isografts [20]. The resulting inflammatory
response of the host contributes to endothelial cell injury and
development of cardiac allograft vasculopathy [21].
We observed a significant increase in incidence of acute
allograft rejection grade Banff 2 in individuals receiving
preemptive therapy of CMV. It seems that frequent subclinical
CMV infection in this subgroup may have contributed to
impaired allograft tolerance. Grade Banff 2 of acute cellular
rejection is characterized by detection of one lymphocytic
infiltrate with focal myocyte damage in EMB. This grade of
acute rejection usually does not cause acute dysfunction of
the allograft. However, destruction of myocytes at this stage
may stimulate native and adaptive immune response and
trigger higher grades of acute allograft rejection and/or
cardiac allograft vasculopathy.9. Study limitations
This study has several limitations. First, relatively small
sample size and non-randomized study design may decrease
the applicability of the results. Second, only CMV-seropositive
HTx recipients were studied. Therefore, the study results
should be applied in similar population. Third, the study
design did not include quantitative assessment of cardiac
allograft vasculopathy with intravascular ultrasound. There-
fore, we cannot comment on the effects of CMVmanagement
on progression of cardiac allograft vasculopathy.10. Conclusions
In comparison with preemptive anti CMV therapy, universal
prophylaxis with valganciclovir in CMV-seropositive HTx
CO R E T VA S A 54 ( 2012 ) e16 –e21 e21recipients reduced more effectively incidence of CMV infec-
tion and acute allograft rejection grade Banff 2 during the first
3 months after transplantation. Prophylactic treatment was
well tolerated and safe.Acknowledgments
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